Related references
Note: Only part of the references are listed.Acute and long-term effects of Roux-en-Y gastric bypass on glucose metabolism in subjects with Type 2 diabetes and normal glucose tolerance
N. B. Jorgensen et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2012)
Intraportal administration of DPP-IV inhibitor regulates insulin secretion and food intake mediated by the hepatic vagal afferent nerve in rats
Kansuke Fujiwara et al.
JOURNAL OF NEUROCHEMISTRY (2012)
Changes in Gastrointestinal Hormone Responses, Insulin Sensitivity, and Beta-Cell Function Within 2 Weeks After Gastric Bypass in Non-diabetic Subjects
S. H. Jacobsen et al.
OBESITY SURGERY (2012)
The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes
Asger Lund et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2011)
Glucose-Dependent Insulinotropic Polypeptide A Bifunctional Glucose-Dependent Regulator of Glucagon and Insulin Secretion in Humans
Mikkel Christensen et al.
DIABETES (2011)
Gastric Bypass Surgery Enhances Glucagon-Like Peptide 1-Stimulated Postprandial Insulin Secretion in Humans
Marzieh Salehi et al.
DIABETES (2011)
Dipeptidyl peptidase-4 inhibition increases portal concentrations of intact glucagon-like peptide-1 (GLP-1) to a greater extent than peripheral concentrations in anaesthetised pigs
K. R. Hjollund et al.
DIABETOLOGIA (2011)
Physiological and Pharmacological Mechanisms through which the DPP-4 Inhibitor Sitagliptin Regulates Glycemia in Mice
Aurelie Waget et al.
ENDOCRINOLOGY (2011)
Impaired Regulation of the Incretin Effect in Patients with Type 2 Diabetes
Jonatan I. Bagger et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Differential Effect of Sham Feeding on Meal Glucose Tolerance in Hypoglycemic vs. Asymptomatic Individuals after Gastric Bypass Surgery
Marzieh Salehi et al.
DIABETES (2011)
Inappropriate glucagon response after oral compared with isoglycemic intravenous glucose administration in patients with type 1 diabetes
Kristine J. Hare et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2010)
Technique of Minimally Invasive Ivor Lewis Esophagectomy
Arjun Pennathur et al.
ANNALS OF THORACIC SURGERY (2010)
Intrameal Hepatic Portal and Intraperitoneal Infusions of Glucagon-Like Peptide-1 Reduce Spontaneous Meal Size in the Rat via Different Mechanisms
Elisabeth B. Ruettimann et al.
ENDOCRINOLOGY (2009)
Pharmacokinetics and Pharmacodynamics of Vildagliptin in Healthy Chinese Volunteers
Pei Hu et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Receptor-mediated activation of gastric vagal afferents by glucagon-like peptide-1 in the rat
V. Bucinskaite et al.
NEUROGASTROENTEROLOGY AND MOTILITY (2009)
Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes
David M. Nathan et al.
DIABETES CARE (2009)
Rosiglitazone no longer recommended
[Anonymous]
LANCET (2008)
The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion
Andrea El-Ouaghlidi et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
Glucagon-like peptide-1 (GLP-1) receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats
Torsten P. Vahl et al.
ENDOCRINOLOGY (2007)
The physiology of glucagon-like peptide 1
Jens Juul Holst
PHYSIOLOGICAL REVIEWS (2007)
Inappropriate suppression of glucagon during OGTT but not during isoglycaemic i.v. glucose infusion contributes to the reduced incretin effect in type 2 diabetes mellitus
F. K. Knop et al.
DIABETOLOGIA (2007)
Suppression of glucagon secretion is lower after oral glucose administration than during intravenous glucose administration in human subjects
J. J. Meier et al.
DIABETOLOGIA (2007)
Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans
JJ Meier et al.
GASTROENTEROLOGY (2006)
Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig
A Plamboeck et al.
DIABETOLOGIA (2005)
Sensory nerves contribute to insulin secretion by glucagon-like peptide-1 in mice
B Ahrén
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY (2004)
Receptor gene expression of glucagon-like peptide-1, but not glucose-dependent insulinotropic polypeptide, in rat nodose ganglion cells
A Nakagawa et al.
AUTONOMIC NEUROSCIENCE-BASIC & CLINICAL (2004)
Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects
T Vilsboll et al.
REGULATORY PEPTIDES (2003)
The influence of GLP-1 on glucose-stimulated insulin secretion -: Effects on β-cell sensitivity in type 2 and nondiabetic subjects
LL Kjems et al.
DIABETES (2003)
Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects
T Vilsboll et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
A safe and noninvasive test for vagal integrity revisited
NS Balaji et al.
ARCHIVES OF SURGERY (2002)
How useful is paracetamol absorption as a marker of gastric emptying? A systematic literature study
M Willems et al.
DIGESTIVE DISEASES AND SCIENCES (2001)
Gastric emptying: the validity of the paracetamol absorption test adjusted for individual pharmacokinetics
AW Medhus et al.
NEUROGASTROENTEROLOGY AND MOTILITY (2001)
No reactive hypoglycaemia in Type 2 diabetic patients after subcutaneous administration of GLP-1 and intravenous glucose
T Vilsboll et al.
DIABETIC MEDICINE (2001)
Share Paper
